The 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry, focused ...

In Part 3 of our Life Sciences Industry Report 2025, we share content from the last twelve months that delved into the ...

The FDA has banned the use of a synthetic red dye used in oral medicines, as well as foods and dietary supplements, more than ...

Generative artificial intelligence (genAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

When healthcare brands leverage data to genuinely understand and connect with HCPs as unique individuals, the result is a ...

Looking ahead to 2025, small biopharma will continue its deliberate and ROI-driven approach to technology adoption. At the ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

Continued pricing pressures from governments and patient groups are driving small molecule CDMOs to focus on reducing the ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...